Navigation Links
Recruitment Completed in Ofatumumab NHL Pivotal Study
Date:9/23/2008

Summary: Genmab has Completed Recruitment of Patients in the Phase III

Study of Ofatumumab in Rituximab Refractory Follicular NHL

COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have been recruited in the study. Data from these patients will be included in the primary efficacy analysis. An additional 31 patients were recruited at a 500 mg dose level prior to amending the study design to include only one dose. Data from these patients will be evaluated for safety and supportive efficacy analysis.

"We have now recruited the last patient into the study and keenly await the results which we hope will show a benefit for follicular NHL patients who need a new treatment option," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site)of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.

About the trial

Patients in this study will receive one infusion of 300 mg of ofatumumab followed by 7 weekly infusions of 1000 mg of ofatumumab. Disease status will be assessed every 3 months until month 24.

The objective of the study is to determine the efficacy and safety of ofatumumab in rituximab refractory follicular NHL. The primary endpoint of the study is objective response
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
5. Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
6. Argonauta Assist(TM)ance: Argonauta Communications Strives to Enhance Site-Based Recruitment Efforts
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
11. Genmab Reaches Milestone in Ofatumumab Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 On September ... sole exhibition focusing on medical design and manufacturing - ... the Shanghai World Expo Exhibition & Convention Center, bringing ... countries and regions to showcase their latest medical-grade raw ... now only one week remaining for free visitor pre-registration ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
(Date:9/16/2014)... Lake Worth, FL (PRWEB) September 16, 2014 ... Millennium Treatment Group, they take care to make sure ... best for them. For some, this may include the ... new online therapy program which gives patients the opportunity ... Millennium Treatment Group can provide medical and clinical care ...
(Date:9/16/2014)... September 16, 2014 Aspen Advisors, a ... has been recognized for its high morale and ... “The Best Small Firms to Work For 2014.” ... with more than 10,000 consultants participating across all major ... satisfaction surveys were conducted, and firms were ranked in ...
(Date:9/16/2014)... cancer may one day be able to predict when ... and sexual functioning, thanks in part to new findings ... the American Society for Radiation Oncology,s 56th Annual Meeting ... from more than 17,000 surveys completed by men diagnosed ... urinary and sexual symptoms changed following each type of ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in ... hypertension association that works to find ways to prevent and ... that affects the functioning of the heart and can lead ... 2.8 years. , What:, Colorado PH in the Park ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Almost all the ... in veins are equally safe and effective, new ... effectiveness of treatments for such blood clots as ... in a lung), Canadian researchers analyzed outcomes associated ... heparin (LMWH) and fondaparinux in combination with vitamin ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News: Most Treatments for Blood Clots Appear Safe, Effective 2
... 3, 2008 A new study presented ... by researchers for Scientific,Food Solutions,( http://www.scientificfoodsolutions.com/pages/clinicals.html ) ... Vitamin C with,Bioperine(R), provides 275 percent faster ... Reece, President of Scientific Food Solutions said, ...
... the American Association for Dental Research,s (AADR) High School ... with the AADR,s 37th Annual Meeting & Exhibition at ... the High School for Health Professions, the Talented and ... School. The program includes a tour of Baylor College ...
... how to eat during seasons key to maintaining health, ... get bombarded on a,regular basis about health, diets and ... According to the Institute for Integrative Nutrition,the largest nutrition ... to maintaining health and wellness, regardless of which,diet you ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration and ... novel thermal energy called plasma for reversing the ... Food and Drug Administration (FDA),clearance to market a ... already cleared by the FDA for treating facial ...
... Campos Ramirez, 60, was sentenced to 10 years in ... defraud Medicare, Assistant Attorney General,Alice S. Fisher of the ... Southern District of Florida announced today. The scheme,represents the ... of the program., Campos was sentenced today in ...
... Ventas, Inc.,(NYSE: VTR ) ("Ventas" or the ... the Company at the Credit Suisse 2008 Global,Real Estate ... at 2:50 p.m.,Eastern Time., The presentation will be ... http://www.ventasreit.com . Any written materials,accompanying the presentation will ...
Cached Medicine News:Health News:Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 2Health News:Institute for Integrative Nutrition Provides Tips to Transition Bodies for Fall, Winter, Spring, Summer Eating 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Owner of Medicare Billing Service Sentenced to 10 Years In Prison For Role in $170 Million Medicare Fraud Scheme 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: